Literature DB >> 11422202

Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis.

K Maasho1, D Wolday, M Edjigu, K Söderström, S Britton, H Akuffo.   

Abstract

Peripheral blood mononuclear cells (PBMC) from cutaneous leishmaniasis patients with ongoing Leishmania aethiopica infection and individuals cured/under treatment from L. infantum or L. donovani infection were stimulated in vitro with LACK, the Leishmania homologue of receptors for activated C kinase. The LACK protein is conserved in related leishmanial species and is expressed both in the promastigote and amastigote stages of Leishmania. Our results show that LACK induced marked NK and some CD8+ cell proliferation in PBMC from cutaneous leishmaniasis patients with active disease. These responses were coupled with high levels of IFN-gamma and IL-10 production. At the concentration tested, the proliferative responses to freeze-thawed Leishmania antigen (Ft-Leish) were higher, while the levels of IFN-gamma were consistently lower than that of LACK. Although cells from individuals cured of leishmaniasis could respond to whole Leishmania lysate by proliferation and IFN-gamma production, there was no evident response to LACK. Ethiopian controls tested at the same time also showed LACK induced proliferation with IFN-gamma and IL-10 responses. Thus LACK reactivity in terms of proliferation and cytokine induction were present in cells from some healthy donors and most of the patients with active lesions, while this response was absent in individuals cured of L. infantum or L. donovani leishmaniasis. Since cure from leishmaniasis often results in life-long protection, and active but not cured patients showed in vitro responses to LACK stimulation, questions arose as to how this highly immunodominant molecule functions during human leishmanisasis. Some possible mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422202      PMCID: PMC1906043          DOI: 10.1046/j.1365-2249.2001.01538.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Skin rash for 15 years.

Authors:  S Montelius; K Maasho; F Pratlong; M Lebbad; L Gregory; H Akuffo
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

2.  Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.

Authors:  A Grönberg; M Ferm; L Tsai; R Kiessling
Journal:  Cell Immunol       Date:  1989-01       Impact factor: 4.868

3.  The inhibitory effect of polymyxin B on endotoxin-induced endogenous pyrogen production.

Authors:  G W Duff; E Atkins
Journal:  J Immunol Methods       Date:  1982-08-13       Impact factor: 2.303

4.  Identification of antigens recognized by T cells in human leishmaniasis: analysis of T-cell clones by immunoblotting.

Authors:  P C Melby; D L Sacks
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors.

Authors:  K Maasho; I Satti; S Nylén; G Guzman; F Koning; H Akuffo
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

6.  Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.

Authors:  I Müller; T Pedrazzini; P Kropf; J Louis; G Milon
Journal:  Int Immunol       Date:  1991-06       Impact factor: 4.823

7.  Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.

Authors:  P Scott; P Caspar; A Sher
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

8.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

9.  Natural killer cell clones can efficiently process and present protein antigens.

Authors:  M G Roncarolo; M Bigler; J B Haanen; H Yssel; R Bacchetta; J E de Vries; H Spits
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

10.  Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.

Authors:  E M Carvalho; O Bacellar; A Barral; R Badaro; W D Johnson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more
  7 in total

1.  Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.

Authors:  S Farajnia; F Mahboudi; S Ajdari; N E Reiner; A Kariminia; M H Alimohammadian
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.

Authors:  Felicitat Todolí; Laia Solano-Gallego; Rafael de Juan; Pere Morell; Maria Del Carmen Núñez; Rodrigo Lasa; Silvia Gómez-Sebastián; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

3.  LACK-specific CD4(+) T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection.

Authors:  Eliane Bourreau; Ghislaine Prévot; Jacques Gardon; Roger Pradinaud; Hitoshi Hasagewa; Geneviève Milon; Pascal Launois
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

4.  Evaluation of amastigote reactive cells in human cutaneous leishmaniasis caused by Leishmania aethiopica.

Authors:  K Maasho; D McMahon-Pratt; J Raita; M Raud; S Britton; L Soong; H Akuffo
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

5.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

6.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

Review 7.  Natural killer cells in experimental and human leishmaniasis.

Authors:  Christian Bogdan
Journal:  Front Cell Infect Microbiol       Date:  2012-05-29       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.